116 related articles for article (PubMed ID: 38517408)
1. Self-assembled nanomicelles for oral delivery of luteolin utilizing the intestinal lymphatic pathway to target pancreatic cancer.
Karole A; Dinakar YH; Sagar P; Mudavath SL
Nanoscale; 2024 Apr; 16(15):7453-7466. PubMed ID: 38517408
[TBL] [Abstract][Full Text] [Related]
2. Hepatoprotective Effects of Bioflavonoid Luteolin Using Self-Nanoemulsifying Drug Delivery System.
Shakeel F; Alamer MM; Alam P; Alshetaili A; Haq N; Alanazi FK; Alshehri S; Ghoneim MM; Alsarra IA
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946581
[TBL] [Abstract][Full Text] [Related]
3. Binary Nanodrug-Delivery System Designed for Leukemia Therapy: Aptamer- and Transferrin-Codecorated Daunorubicin- and Luteolin-Coloaded Nanoparticles.
Zhu Y; Zhang W; Chen J
Drug Des Devel Ther; 2023; 17():1-13. PubMed ID: 36636745
[TBL] [Abstract][Full Text] [Related]
4. Delivery luteolin with folacin-modified nanoparticle for glioma therapy.
Wu C; Xu Q; Chen X; Liu J
Int J Nanomedicine; 2019; 14():7515-7531. PubMed ID: 31571861
[TBL] [Abstract][Full Text] [Related]
5. Luteolin and Gemcitabine Protect Against Pancreatic Cancer in an Orthotopic Mouse Model.
Johnson JL; Dia VP; Wallig M; Gonzalez de Mejia E
Pancreas; 2015 Jan; 44(1):144-51. PubMed ID: 25237909
[TBL] [Abstract][Full Text] [Related]
6. Mucoadhesive nanoemulsion enhances brain bioavailability of luteolin after intranasal administration and induces apoptosis to SH-SY5Y neuroblastoma cells.
Diedrich C; Camargo Zittlau I; Schineider Machado C; Taise Fin M; Maissar Khalil N; Badea I; Mara Mainardes R
Int J Pharm; 2022 Oct; 626():122142. PubMed ID: 36064075
[TBL] [Abstract][Full Text] [Related]
7. DPYD, down-regulated by the potentially chemopreventive agent luteolin, interacts with STAT3 in pancreatic cancer.
Kato H; Naiki-Ito A; Suzuki S; Inaguma S; Komura M; Nakao K; Naiki T; Kachi K; Kato A; Matsuo Y; Takahashi S
Carcinogenesis; 2021 Jul; 42(7):940-950. PubMed ID: 33640964
[TBL] [Abstract][Full Text] [Related]
8. Construction of benzyl isothiocyanate-loaded fish skin gelatin-luteolin compound emulsion delivery system, and its digestion and absorption characteristics.
Liu Z; Lin S; Liu W; Nakamura Y; Tang Y
J Sci Food Agric; 2023 Mar; 103(4):1864-1873. PubMed ID: 36571447
[TBL] [Abstract][Full Text] [Related]
9. Luteolin-Loaded Nanoparticles for the Treatment of Melanoma.
Fu QT; Zhong XQ; Chen MY; Gu JY; Zhao J; Yu DH; Tan F
Int J Nanomedicine; 2023; 18():2053-2068. PubMed ID: 37101838
[TBL] [Abstract][Full Text] [Related]
10. Folic acid-modified ROS-responsive nanoparticles encapsulating luteolin for targeted breast cancer treatment.
Wang Y; Wang Q; Feng W; Yuan Q; Qi X; Chen S; Yao P; Dai Q; Xia P; Zhang D; Sun F
Drug Deliv; 2021 Dec; 28(1):1695-1708. PubMed ID: 34402706
[TBL] [Abstract][Full Text] [Related]
11. Fabrication of Luteolin Loaded Zein-Caseinate Nanoparticles and its Bioavailability Enhancement in Rats.
Xu QT; Zhang WX; Xu HX; Zhang QF
J Pharm Sci; 2023 Dec; 112(12):3056-3066. PubMed ID: 37356712
[TBL] [Abstract][Full Text] [Related]
12. Phytochylomicron as a dual nanocarrier for liver cancer targeting of luteolin: in vitro appraisal and pharmacodynamics.
Elnaggar YS; Elsheikh MA; Abdallah OY
Nanomedicine (Lond); 2018 Jan; 13(2):209-232. PubMed ID: 29199881
[TBL] [Abstract][Full Text] [Related]
13. Critical determinant of intestinal permeability and oral bioavailability of pegylated all trans-retinoic acid prodrug-based nanomicelles: Chain length of poly (ethylene glycol) corona.
Li Z; Han X; Zhai Y; Lian H; Zhang D; Zhang W; Wang Y; He Z; Liu Z; Sun J
Colloids Surf B Biointerfaces; 2015 Jun; 130():133-40. PubMed ID: 25907597
[TBL] [Abstract][Full Text] [Related]
14. Improving Oral Bioavailability of Luteolin Nanocrystals by Surface Modification of Sodium Dodecyl Sulfate.
Liu J; Sun Y; Cheng M; Liu Q; Liu W; Gao C; Feng J; Jin Y; Tu L
AAPS PharmSciTech; 2021 Apr; 22(3):133. PubMed ID: 33855636
[TBL] [Abstract][Full Text] [Related]
15. A bubble bursting-mediated oral drug delivery system that enables concurrent delivery of lipophilic and hydrophilic chemotherapeutics for treating pancreatic tumors in rats.
Chen KH; Miao YB; Shang CY; Huang TY; Yu YT; Yeh CN; Song HL; Chen CT; Mi FL; Lin KJ; Sung HW
Biomaterials; 2020 Oct; 255():120157. PubMed ID: 32535305
[TBL] [Abstract][Full Text] [Related]
16. Novel luteolin@pro-phytomicelles: In vitro characterization and in vivo evaluation of protection against drug-induced hepatotoxicity.
Song K; Zhou L; Wang C; Yuan Z; Cao Q; Wu X; Li M
Chem Biol Interact; 2022 Sep; 365():110095. PubMed ID: 35970426
[TBL] [Abstract][Full Text] [Related]
17. Design and Optimization of Orally Administered Luteolin Nanoethosomes to Enhance Its Anti-Tumor Activity against Hepatocellular Carcinoma.
Elsayed MMA; Okda TM; Atwa GMK; Omran GA; Abd Elbaky AE; Ramadan AEH
Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34063274
[TBL] [Abstract][Full Text] [Related]
18. One-step self-assembled nanomicelles for improving the oral bioavailability of nimodipine.
Luo JW; Zhang ZR; Gong T; Fu Y
Int J Nanomedicine; 2016; 11():1051-65. PubMed ID: 27042060
[TBL] [Abstract][Full Text] [Related]
19. Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro.
Johnson JL; Gonzalez de Mejia E
Food Chem Toxicol; 2013 Oct; 60():83-91. PubMed ID: 23871783
[TBL] [Abstract][Full Text] [Related]
20. The dietary flavone luteolin epigenetically activates the Nrf2 pathway and blocks cell transformation in human colorectal cancer HCT116 cells.
Zuo Q; Wu R; Xiao X; Yang C; Yang Y; Wang C; Lin L; Kong AN
J Cell Biochem; 2018 Nov; 119(11):9573-9582. PubMed ID: 30129150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
